ace-tRNA Therapeutics for Retinal PTC Read-Through Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for treating vision loss and blindness caused by premature termination codons (PTCs) are limited, particularly for conditions like Leber congenital amaurosis, as they face challenges in drug delivery to the retina due to the blood-retina barrier and lack a generalizable in vivo delivery method for PTC repair.
Innovation Solution
Development of tRNA therapeutics, specifically ace-tRNA, to read through PTCs in retinal cells, using vectors and expression cassettes for effective protein function restoration and vision restoration, utilizing methods like sub-retinal and suprachoroidal routes for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Area of stationary object
If systemic drug delivery is used to treat retinal diseases, then the treatment can reach multiple areas of the retina, but the blood-retina barrier restricts adequate drug availability in the retina
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver tRNA therapeutics across the blood-retina barrier. The AAV vector serves as a mediator that can traverse the barrier and deliver the therapeutic payload directly to retinal cells, overcoming the restriction imposed by the blood-retina barrier while maintaining systemic delivery capabilities
Solution Approach 2:
The patent changes the physical and chemical parameters of the drug delivery system by using viral vectors instead of conventional small molecule drugs. This parameter change enables the delivery system to interact with and cross the blood-retina barrier, thereby improving drug availability in the retina while maintaining broad coverage
2Duration of action of stationary object
If intravitreal administration is used for drug delivery to the retina, then multiple dosing intervals are tolerated, but targeting to the posterior retina poses diffusion limitations
Solution Approach 1:
The patent employs AAV vectors as intermediary delivery vehicles that can actively transport tRNA therapeutics to the posterior retina, overcoming the passive diffusion limitations of intravitreal administration. The viral vector mediator enables targeted delivery to distant retinal regions while maintaining the dosing interval benefits
3Reliability
If AAV-mediated gene therapy is used for biallelic RPE65 mutation, then specific gene therapy approval is achieved, but it only treats a fraction of LCA mutations
Solution Approach 1:
The patent creates a universal tRNA therapeutic platform delivered by AAV vectors that can address multiple different PTC-causing mutations across various genes. This multi-functional approach maintains the reliability of AAV-mediated delivery while significantly expanding adaptability to treat diverse LCA mutations beyond just RPE65 biallelic mutations
Solution Approach 2:
The patent segments the therapeutic approach into a modular tRNA therapeutic platform that can be tailored to specific PTC mutations while using a common AAV delivery system. This segmentation allows the core delivery mechanism to remain reliable and approved while enabling customization for different mutation types and genes
4Ease of manufacture
If limited viral and non-viral delivery options are used for nucleic acid-based therapies, then delivery methods are available, but a generalizable in vivo deliverable is lacking
Solution Approach 1:
The patent develops a universal AAV vector-based delivery platform that can deliver tRNA therapeutics for treating various PTC-causing retinal diseases. This platform provides both ease of manufacture through established AAV production methods and generalizability across multiple disease indications and mutation types, filling the gap for a truly generalizable in vivo deliverable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tRNA therapeutics provide a universal and precise method to restore protein function and vision by repairing PTCs across multiple genes, offering a long-lasting gene therapy for inherited blinding disorders with minimal off-target effects.
Implementation Method 1
tRNA therapeutics for treating vision loss and blindness... read through one or more premature termination codons (PTCs)... provide a universal and precise method to restore protein function by repairing PTCs
Data Source
AI summary
Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.